Abetimus

A synthetic drug used in the treatment of systemic lupus erythematosus

Abetimus
File:Abetimus.svg
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Abetimus is a synthetic immunosuppressive drug designed for the treatment of systemic lupus erythematosus (SLE), an autoimmune disease characterized by the body's immune system attacking its own tissues. Abetimus is specifically engineered to reduce the production of anti-double-stranded DNA antibodies, which are implicated in the pathogenesis of SLE.

Mechanism of Action

Abetimus functions by mimicking the structure of double-stranded DNA (dsDNA), thereby acting as a decoy for the B cells that produce anti-dsDNA antibodies. By binding to these B cells, abetimus prevents them from producing harmful antibodies that can lead to tissue damage in patients with SLE. This mechanism helps in reducing the inflammatory response and subsequent organ damage associated with the disease.

Clinical Use

Abetimus is primarily used in patients with SLE who have high levels of anti-dsDNA antibodies. It is administered as part of a comprehensive treatment plan that may include other immunosuppressants, corticosteroids, and antimalarial drugs like hydroxychloroquine. The goal of treatment with abetimus is to achieve disease remission and prevent flare-ups of SLE symptoms.

Side Effects

Common side effects of abetimus include injection site reactions, such as redness and swelling, as well as flu-like symptoms such as fever and fatigue. More serious side effects can include allergic reactions and increased risk of infections due to its immunosuppressive action.

Development and Approval

Abetimus was developed as a novel approach to specifically target the pathogenic antibodies in SLE. Its development involved extensive clinical trials to assess its efficacy and safety. However, its approval status may vary by country, and it is important for healthcare providers to consider the latest guidelines and research when prescribing this medication.

Related pages

• Systemic lupus erythematosus
• Immunosuppressive drug
• Autoimmune disease
• B cell
• Antibody

• Abetimus
  Abetimus